Heterogeneity of Prostate-specific Membrane Antigen (PSMA) and PSMA-ligand Uptake Detection Combining Autoradiography and Postoperative Pathology in Primary Prostate Cancer

Overview

Journal EJNMMI Res

Date 2023 Nov 16

PMID 37971546

Authors

Hui Wang

Marianne Remke

Thomas Horn

Kristina Schwamborn

Yiyao Chen

Katja Steiger

Wilko Weichert

Hans-Jurgen Wester

Margret Schottelius

Wolfgang A Weber

Matthias Eiber

Affiliations

Soon will be listed here.

Abstract

Background: Targeting prostate-specific membrane antigen (PSMA) has been highly successful for imaging and treatment of prostate cancer. However, heterogeneity in immunohistochemistry indicates limitations in the effect of imaging and radionuclide therapy of multifocal disease. Tc-PSMA-I&S is a γ-emitting probe, which can be used for intraoperative lesion detection and postsurgical autoradiography (ARG). We aimed to study its intraprostatic distribution and compared it with (immuno)-histopathology.

Results: Seventeen patients who underwent RGS between 11/2018 and 01/2020 with a total of 4660 grids were included in the preliminary analysis. Marked intratumor and intra-patient heterogeneity of PSMA expression was detected, and PSMA negative foci were observed in all samples (100%). Heterogeneous intra-patient PSMA-ligand uptake was observed, and no significant correlation was present between the degree of heterogeneity of PSMA expression and PSMA-ligand uptake. Higher PSMA-ligand uptake was observed in GS ≥ 8 than GS < 8 (p < 0.001). The appearance of Gleason Pattern (GP) 4 was strongly associated with higher uptake (coefficient: 0.43, p < 0.001), while GP 5 also affected the uptake (coefficient: 0.07, p < 0.001).

Conclusion: PSMA expression and PSMA-ligand uptake show marked heterogeneity. Prostate carcinoma with GP 4 showed significantly higher uptake compared with non-neoplastic prostate tissue. Our analyses extend the scope of applications of radiolabeled PSMA-ligands to ARG for identifying high-grade disease and using its signal as a noninvasive biomarker in prostate cancer.

Citing Articles

Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis.

Bilgin G, Bilgin C, Orscelik A, Burkett B, Thorpe M, Johnson D Ann Nucl Med. 2024; 38(11):865-876.

PMID: 39287742 DOI: 10.1007/s12149-024-01978-6.

References

Horn T, Kronke M, Rauscher I, Haller B, Robu S, Wester H . Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery.... Eur Urol. 2019; 76(4):517-523. DOI: 10.1016/j.eururo.2019.03.045. View

Ferraro D, Rupp N, Donati O, Messerli M, Eberli D, Burger I . 68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue. Clin Nucl Med. 2019; 44(4):e291-e293. DOI: 10.1097/RLU.0000000000002473. View

Smith-Jones P, Vallabahajosula S, Goldsmith S, Navarro V, Hunter C, Bastidas D . In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000; 60(18):5237-43. View

Schwarzenboeck S, Rauscher I, Bluemel C, Fendler W, Rowe S, Pomper M . PSMA Ligands for PET Imaging of Prostate Cancer. J Nucl Med. 2017; 58(10):1545-1552. DOI: 10.2967/jnumed.117.191031. View

Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen J, Huang K . Immunohistochemical Validation of PSMA Expression Measured by Ga-PSMA PET/CT in Primary Prostate Cancer. J Nucl Med. 2017; 59(2):238-243. DOI: 10.2967/jnumed.117.195172. View

Cytawa W, Kircher S, Kubler H, Werner R, Weber S, Hartrampf P . Diverse PSMA expression in primary prostate cancer: reason for negative [Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens. Eur J Nucl Med Mol Imaging. 2022; 49(11):3938-3949. DOI: 10.1007/s00259-022-05831-8. View

Epstein J, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P . The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2015; 40(2):244-52. DOI: 10.1097/PAS.0000000000000530. View

Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A . Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015; 68(3):530-4. DOI: 10.1016/j.eururo.2015.04.034. View

Mannweiler S, Amersdorfer P, Trajanoski S, Terrett J, King D, Mehes G . Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2008; 15(2):167-72. DOI: 10.1007/s12253-008-9104-2. View

10.

Heck M, Tauber R, Schwaiger S, Retz M, DAlessandria C, Maurer T . Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018; 75(6):920-926. DOI: 10.1016/j.eururo.2018.11.016. View

11.

Sweat S, Pacelli A, Murphy G, Bostwick D . Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998; 52(4):637-40. DOI: 10.1016/s0090-4295(98)00278-7. View

12.

Hupe M, Philippi C, Roth D, Kumpers C, Ribbat-Idel J, Becker F . Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Front Oncol. 2019; 8:623. PMC: 6307416. DOI: 10.3389/fonc.2018.00623. View

13.

Davis M, Bennett M, Thomas L, Bjorkman P . Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A. 2005; 102(17):5981-6. PMC: 556220. DOI: 10.1073/pnas.0502101102. View

14.

Chatalic K, Heskamp S, Konijnenberg M, Molkenboer-Kuenen J, Franssen G, Clahsen-van Groningen M . Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016; 6(6):849-61. PMC: 4860893. DOI: 10.7150/thno.14744. View

15.

Maley C, Aktipis A, Graham T, Sottoriva A, Boddy A, Janiszewska M . Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017; 17(10):605-619. PMC: 5811185. DOI: 10.1038/nrc.2017.69. View

16.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

17.

Kawakami M, Nakayama J . Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997; 57(12):2321-4. View

18.

Perner S, Hofer M, Kim R, Shah R, Li H, Moller P . Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007; 38(5):696-701. DOI: 10.1016/j.humpath.2006.11.012. View

19.

Maurer T, Gschwend J, Rauscher I, Souvatzoglou M, Haller B, Weirich G . Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2015; 195(5):1436-1443. DOI: 10.1016/j.juro.2015.12.025. View

20.

Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff C . Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016; 7(11):12477-88. PMC: 4914299. DOI: 10.18632/oncotarget.7245. View